Posted by George Tice | 17/12/2019
I have worked for Elanco for over 20 years and have never been more excited about the science of animal health emerging in response to the challenge of antimicrobial resistance (AMR) writes George Tice, Senior Director Market Access International.
A number of my colleagues are participating The 3rd International Symposium on Alternatives to Antibiotics: Challenges and Solutions in Animal Health and Production in Bangkok this month. It’s a really important forum to assess scientific advancements in the field of alternatives to antibiotics, and brings together multiple stakeholders to consider regulatory pathways required for development and commercialization of new technologies.
Elanco’s antimicrobial stewardship journey has included a number of related aspects. Encapsulated within our 8-Point Plan, our approach has included understanding the science and supporting customers with data analytics to better detect and plan early interventions in livestock diseases, and developing novel technologies that help to reduce the need for medically important antibiotics. We also support our customers to help them understand emerging regulatory environments and consumer perspectives.
My colleagues presenting at the Symposium in Bangkok are doing important work to understand and advance the science related to AMR – from monitoring transmissible antibiotic resistance genes in avian pathogenic E-coli, to reducing the prevalence of liver abscess in feedlot cattle, to defining the role of probiotics and enzymes in improving intestinal health in broilers.
A separate lunchtime symposium will focus on the importance of Salmonella control as part of the poultry industry’s commitment to controlling this zoonotic disease, ensuring food safety and addressing AMR. Europe’s experience in particular provides a great example and opportunity for learning in terms of the policy and practice of Salmonella control.
Elanco takes its commitment to antibiotic alternatives very seriously. We have made significant pipeline investments, we strongly support stewardship of the existing antibiotic toolkit, and we have launched new innovations such as nutritional products and vaccines. While we continue to supply medically important antibiotics within responsible use guidelines where they are needed, our efforts are focused on finding innovative alternatives.
Possibly even more important than the science, is multi-stakeholder collaboration to ensure society doesn’t get ahead of the science, and to ensure that alternatives to antibiotics can be commercialized with confidence and speed as soon as they are ready. The symposium in Bangkok is advancing both science and stakeholder collaboration for healthy animals and a healthy planet.